Literature DB >> 10405716

Renal neoplasms amenable to partial nephrectomy: MR imaging.

E S Pretorius1, E S Siegelman, P Ramchandani, T Cangiano, M P Banner.   

Abstract

PURPOSE: To determine the magnetic resonance (MR) imaging characteristics of renal lesions in patients who undergo technically successful partial nephrectomy.
MATERIALS AND METHODS: Between February 1991 and September 1997, 38 patients (41 lesions) who underwent partial nephrectomy at a single institution were preoperatively evaluated with contrast material-enhanced, multiplanar, surface-coil MR imaging. Imaging findings that could affect the decision to perform partial nephrectomy were retrospectively evaluated: tumor size; tumor location; presence of pseudocapsule; suspected tumor invasion of renal sinus fat, renal collecting system, renal vein, or perinephric fat; and morphologic and physiologic status of the contralateral kidney. Correlation was made with surgical and pathologic findings.
RESULTS: Thirty-three of 41 lesions (80%) were renal cell carcinomas, five were oncocytic neoplasms (12%), two were hemorrhagic cysts (5%), and one was an angiomyolipoma (2%). Twenty-four of 41 (59%) lesions had pseudocapsules. In most cases, the perinephric fat (n = 38 [93%]), the renal sinus fat (n = 31 [76%]), and the renal collecting system (n = 39 [95%]) were correctly interpreted as being uninvolved by tumor.
CONCLUSION: Renal neoplasms amenable to partial nephrectomy can be identified and characterized with contrast-enhanced, multiplanar, surface-coil MR imaging.

Entities:  

Mesh:

Year:  1999        PMID: 10405716     DOI: 10.1148/radiology.212.1.r99jl3228

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

1.  Papillary renal cell carcinoma in allograft kidney.

Authors:  Catherine Roy; Sofiane El Ghali; Xavier Buy; Véronique Lindner; Afshin Gangi
Journal:  Eur Radiol       Date:  2004-09-17       Impact factor: 5.315

2.  MR Imaging of papillary renal neoplasms: potential application for characterization of small renal masses.

Authors:  Catherine Roy; Benoit Sauer; Véronique Lindner; Hervé Lang; Christian Saussine; Didier Jacqmin
Journal:  Eur Radiol       Date:  2006-06-07       Impact factor: 5.315

3.  Morphological, contrast-enhanced and spin labeling perfusion imaging for monitoring of relapse after RF ablation of renal cell carcinomas.

Authors:  Andreas Boss; Petros Martirosian; Christina Schraml; Stephan Clasen; Michael Fenchel; Artistotelis Anastasiadis; Claus D Claussen; Philippe L Pereira; Fritz Schick
Journal:  Eur Radiol       Date:  2006-01-27       Impact factor: 5.315

4.  Characterization of renal cell carcinoma using agent detection imaging: comparison with gray-scale US.

Authors:  Byung Kwan Park; Seung Hyup Kim; Hyuck Jae Choi
Journal:  Korean J Radiol       Date:  2005 Jul-Sep       Impact factor: 3.500

Review 5.  Correlating Preoperative Imaging with Histologic Subtypes of Renal Cell Carcinoma and Common Mimickers.

Authors:  Jennifer Gordetsky; Jessica Zarzour
Journal:  Curr Urol Rep       Date:  2016-07       Impact factor: 3.092

Review 6.  Update on oncocytoma.

Authors:  Stephen M Schatz; Michael M Lieber
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 3.092

7.  Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.

Authors:  Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa
Journal:  Eur Radiol       Date:  2012-08-21       Impact factor: 5.315

Review 8.  MRI of the kidney-state of the art.

Authors:  J J Nikken; G P Krestin
Journal:  Eur Radiol       Date:  2007-07-24       Impact factor: 5.315

Review 9.  MRI phenotype in renal cancer: is it clinically relevant?

Authors:  Naomi Campbell; Andrew B Rosenkrantz; Ivan Pedrosa
Journal:  Top Magn Reson Imaging       Date:  2014-04

Review 10.  Imaging Advances in the Management of Kidney Cancer.

Authors:  Katherine M Krajewski; Ivan Pedrosa
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.